Compositions and methods of treating lupus nephritis
AssigneeGenentech, Inc.
InventorPaul Brunetta
Life of this patent
Estimating the term…
Abstract
The invention provides methods for treating or delaying progression of lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. The invention also provides methods for treating or delaying progression of rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) in an individual. In some embodiments, the methods comprise administering an effective amount of an anti-CD20 antibody.
Claims51
A method for treating lupus nephritis in an individual that has active lupus nephritis, comprising administering to the individual at least a first antibody exposure to obinutuzumab and a second antibody exposure to obinutuzumab;
- wherein the first antibody exposure comprises two doses of obinutuzumab administered about 2 weeks apart, wherein both doses of the first antibody exposure are about 1000 mg of obinutuzumab administered intravenously;
- wherein the second antibody exposure comprises two doses of obinutuzumab administered about 2 weeks apart, wherein both doses of the second antibody exposure are about 1000 mg of obinutuzumab administered intravenously;
- wherein the first dose of the second antibody exposure is not provided until about 24 weeks after the first dose of the first antibody exposure;
- and
- wherein the individual is a human.
A method for treating lupus nephritis in an individual that has active class III or class IV lupus nephritis, comprising administering to the individual:
- (a) at least a first antibody exposure to obinutuzumab and a second antibody exposure to obinutuzumab, and (b) a standard of care treatment;
- wherein the first antibody exposure comprises two doses of obinutuzumab administered about 2 weeks apart, wherein both doses of the first antibody exposure are about 1000 mg of obinutuzumab administered intravenously;
- wherein the second antibody exposure comprises two doses of obinutuzumab administered about 2 weeks apart, wherein both doses of the second antibody exposure are about 1000 mg of obinutuzumab administered intravenously;
- wherein the first dose of the second antibody exposure is not provided until about 24 weeks after the first dose of the first antibody exposure;
- and
- wherein the individual is a human.
A method for treating lupus nephritis in an individual that has active class III or class IV lupus nephritis, comprising administering to the individual:
- (a) at least a first antibody exposure to obinutuzumab and a second antibody exposure to obinutuzumab, (b) mycophenolate mofetil (MMF), and (c) a glucocorticoid or corticosteroid;
- wherein the first antibody exposure comprises two doses of obinutuzumab administered about 2 weeks apart, wherein both doses of the first antibody exposure are about 1000 mg of obinutuzumab administered intravenously;
- wherein the second antibody exposure comprises two doses of obinutuzumab administered about 2 weeks apart, wherein both doses of the second antibody exposure are about 1000 mg of obinutuzumab administered intravenously;
- wherein the first dose of the second antibody exposure is not provided until about 24 weeks after the first dose of the first antibody exposure;
- wherein the individual is a human;
- and
- wherein the method results in the individual achieving a urinary protein to creatinine ratio (UPCR) of <0.5 g/g.
A method for treating lupus nephritis in an individual that has active lupus nephritis, comprising administering to the individual at least four intravenous infusions of obinutuzumab;
- wherein each infusion comprises 1,000 mg of obinutuzumab;
- wherein the infusions are administered at weeks 0, 2, 24, and 26;
- and
- wherein the individual is a human.
Dependencies are inferred from the claim text.